UPB (Upstream Bio Corp) Net earnings per share (EPS TTM)

Upstream Bio Inc (UPB) utilizes robotic bioscreening to identify therapeutic antibodies, accelerating the development of asthma medications. The rolling year EPS percentage change chart visualizes this technological progress, with the latest value recorded as -31.80. While the company currently relies on investor capital, successful trials will secure its long-term pricing power in the market.
UPB (Upstream Bio Corp): analytical breakdowns and indicator data

For Upstream Bio Inc (UPB), which is developing a unique niche of TSLP inhibitors in immunology, the annual EPS TTM chart reflects the monetization efficiency of its biotechnological developments. This indicator measures the percentage change in net income per share over twelve months, allowing investors to assess the growth rate of the company's real earnings relative to the previous period to determine the fundamental value of the business.